title: Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
abstract: This post hoc analysis investigates the effect of vortioxetine on cognitive functioning and depressive symptoms in working adults with major depressive disorder (MDD).
  
  
  
  Population data from FOCUS, a double-blind, randomized, placebo-controlled study investigating the efficacy of vortioxetine versus placebo on cognitive functioning and depression in patients with MDD, were used to analyze mean change from baseline scores for the Digit Symbol Substitution Test (DSST), Trail Making Test A/B (TMT-A/B), Stroop, and Perceived Deficits Questionnaire (PDQ). FOCUS, conducted from December 2011 through May 2013, included adult patients with recurrent MDD according to DSM-IV-TR criteria. Change in depression severity (Montgomery-Asberg Depression Rating Scale [MADRS] total score) was analyzed using data from 3 additional short-term placebo-controlled studies (2 of which included duloxetine) and 1 relapse prevention study. Analyses were done according to patients' working status at baseline and workplace position. All analyses were made versus placebo.
  
  
  
  In FOCUS, the effect versus placebo on the DSST was 5.6 for 10 mg and 5.0 for 20 mg (P < .001 for both doses) in working patients; the effect was 4.0 (P < .001 for both doses) in total study population. The effect remained significant when adjusting for change in MADRS. In patients with "professional" positions, the effect was 9.2 for 10 mg (P = .006) and 9.0 for 20 mg (P = .001). A similar pattern of results was also observed for TMT-A/B, Stroop, PDQ, and MADRS total score. The efficacy of duloxetine was not different in working patients (MADRS).
  
  
  
  The beneficial effects of vortioxetine on objective and subjective measures of cognitive functioning are greater in working patients with MDD; the observed benefits were independent of improvement in depressive symptoms.
  
  
  
  This study is a secondary analysis of data from 5 registered trials: ClinicalTrials.gov identifiers: NCT01422213, NCT00635219, NCT00735709, NCT01140906, NCT00596817​.
authors: Department of Psychiatry and Pharmacology, Mood Disorders Psychopharmacology Unit, University of Toronto, University Health Network, 399 Bathurst St, Toronto, ON, M5T 2S8, Canada. roger.mcintyre@uhn.ca.|Department of Psychiatry and Pharmacology, Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Ontario, Canada.
authors: Roger S
authors: RS
authors: McIntyre
authors: H. Lundbeck A/S, Valby, Denmark.
authors: Ioana
authors: I
authors: Florea
authors: Lundbeck SAS, Issy-les-Moulineaux, France.
authors: Brigitte
authors: B
authors: Tonnoir
authors: H. Lundbeck A/S, Valby, Denmark.
authors: Henrik
authors: H
authors: Loft
authors: Department of Psychiatry, University of British Columbia, Vancouver, Canada.
authors: Raymond W
authors: RW
authors: Lam
authors: H. Lundbeck A/S, Valby, Denmark.
authors: Michael Cronquist
authors: MC
authors: Christensen
mesh_terms: D000328:Adult; D060825:Cognitive Dysfunction / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004526:Efficiency; D005260:Female; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011594:Psychometrics; D013440:Sulfides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D000078784:Vortioxetine
chemical_list: D010879:Piperazines; D013440:Sulfides; D000078784:Vortioxetine